Adipogen/CX-4945 . hydrochloride/AG-CR1-3629-M025/25 mg
商品编号：
AG-CR1-3629-M025
品牌：
Adipogen Inc
市场价：
¥9900.00
美元价：
5940.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Silmitasertib . HCl; 8-Carboxy-N-(3-chlorophenyl)benzo[c][2,6] naphthyridin-5-aminium chloride |
| Product Type | Chemical |
| Properties | |
| Formula | C19H12ClN3O2 . HCl |
| MW | 349.8 . 36.5 |
| CAS | 1009820-21-6 (free acid) |
| Purity Chemicals | ≥98% |
| Appearance | Yellow solid. |
| Solubility | Soluble in DMSO. Insoluble in water. |
| InChi Key | OBOIGMDUOMSAHW-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Orally active, potent and selective ATP-competitive inhibitor of the protein kinase CK2 (IC50=1nM).
- Anticancer compound. Inhibits proliferation in a panel of cancer cell lines that overexpress CK2. Inhibited migration, blocks survival and induces apoptosis in cancer stem cells, glioblastomas and leukemia cells.
- Shown to decrease the glucose metabolism in cancer cells.
- Potent inhibitor of Cdc2-like kinases (Clks) in vitro, consequently interfering with alternative splicing.
- Potent ATP-competitive inhibitor of DYRK1A (IC50=6.8nM), DYRK1B (IC50=6.4nM) and DYRK3 (IC50=18nM), involved in neurodegeneration-associated diseases.
- CK2α deletion selectively increased M3 muscarinic receptors (M3Rs)-mediated insulin secretion from pancreatic islets.
- Promoted cAMP-induced thermogenesis in white adipocytes.
- CK2 inhibition ameliorates diet-induced obesity and insulin resistance in mice in vivo by promoting UCP1-dependent thermogenesis.
Product References
- CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy: A. Siddiqui-Jain, et al.; Cancer Res. 70, 10288 (2010)
- Structural basis of CX-4945 binding to human protein kinase CK2: A.D. Ferguson, et al.; FEBS Lett. 585, 104 (2011)
- Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer: F. Pierre, et al.; J. Med. Chem. 54, 635 (2011)
- Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer: F. Pierre, et al.; Mol. Cell Biochem. 356, 37 (2011)
- CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway: R.C. Prins, et al.; Leukemia 27, 2094 (2013)
- CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells: M.J. Ku, et al.; Bioorg. Med. Chem. Lett. 23, 5609 (2013)
- Identification of a novel function of CX-4945 as a splicing regulator: H. Kim, et al.; PLos One 9, e94978 (2014)
- Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia: L.R. Martins, et al.; Leukemia 28, 179 (2014)
- Phosphoproteomics identifies CK2 as a negative regulator of beige adipocyte thermogenesis and energy expenditure: K. Shinoda, et al.; Cell Metab. 22, 997 (2015)
- CK2 acts as a potent negative regulator of receptor-mediated insulin release in vitro and in vivo: M. Rossi, et al.; PNAS 112, E6818 (2015)
- The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies: H.J. Chon, et al.; Front. Pharmacol. 6, 70 (2015)
- A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition: H. Kim, et al.; Dis. Model Mech. 9, 839 (2016)
- Targeting protein kinase CK2 suppresses bladder cancer cell survival via the glucose metabolic pathway: X. Zhang, et al.; Oncotarget 7, 87361 (2016)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
